Positive resultss Positive Results from Phase 2 trial of MBX-8025Metabolex, a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 2 trial of MBX – 8025th A summary of results on 1 at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension November 2008 presented. MBX-8025 is an oral drug candidate for for the treatment of dyslipidemia..
Treatment with MBX-8025 was well tolerated, with no reports of drug-related serious adverse events reported compared and potential security risks than with placebo and / or Lipitor. With with MBX-8025 alone, a 30 percent reduction in triglycerides and 20 percent decrease in LDL cholesterol compared with placebo after 8 weeks of treatment. And 12 percent , Furthermore MBX-8025 HDL cholesterol by about 8 percent increased. The triglyceride – lowering effect of MBX-8025 in combination with in combination with Lipitor without raising LDL cholesterol.Publish. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All Rights Reserved part.. Partner Examines Influence Of Health Care Industry to brokering compromise on Massachusetts Reform Package.
The Boston Globe Monday investigates how in the Boston area helping health management ‘forge a trade ‘of health insurance law after leaders in the status the House and Senate deadlocked on legislation would increase the number the uninsured in the state.